Compare MITK & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITK | GYRE |
|---|---|---|
| Founded | 1983 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.5M | 679.4M |
| IPO Year | 1995 | 2004 |
| Metric | MITK | GYRE |
|---|---|---|
| Price | $15.36 | $7.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $15.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 966.5K | 46.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.43 | N/A |
| EPS | ★ 0.06 | 0.02 |
| Revenue | ★ $45,390,000.00 | $275,000.00 |
| Revenue This Year | $9.55 | $19.88 |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | ★ $255.17 | $403.25 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.53 | $6.58 |
| 52 Week High | $15.80 | $11.77 |
| Indicator | MITK | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 60.17 | 41.49 |
| Support Level | $13.33 | $6.87 |
| Resistance Level | $15.70 | $8.28 |
| Average True Range (ATR) | 0.62 | 0.34 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 85.25 | 6.98 |
Mitek Systems Inc is engaged in the development, sale, and service of proprietary software solutions related to mobile imaging. The firm is a software development company with expertise in artificial intelligence, and machine learning. It serves more than 7,900 financial services organizations, financial technology (fintech) brands, telecommunications companies, and marketplace brands across the globe. The company's Mobile Deposit solution is used by consumers for mobile check deposits. The company's Mobile Verify verifies a user's identity online, enabling organizations to build safer digital communities, whereas CheckReader enables financial institutions to automatically extract data from a check image received across any deposit channel - branch, ATM, RDC, and mobile.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.